Chairman of the Board of Directors
David Greenwood joined our Board in April 2019 and was appointed as chairman in April 2021. Mr. Greenwood brings to CohBar more than 40 years of financial and operational experience in biotechnology and investment banking. From December 2010 until its recent merger with Gurnet Point Capital in November 2018, he served on the Board of Directors of Corium International, Inc. (formerly NASDAQ: CORI), a leading biopharmaceutical company developing and commercializing transdermal healthcare products. During his tenure as Executive Chairman from June 2012 to December 2016, and Chairman beginning in 2016, Mr. Greenwood most notably led the company through a successful IPO and helped raised substantial capital in the equity and debt markets.
From 1995 through December 2011, Mr. Greenwood served in a number of executive and leadership roles, including Chief Financial Officer, President, Chief Executive Officer and Director at Geron Corporation, a biotechnology company focused on regenerative medicine and cancer. Previously, he served as Chairman of both Geron Bio-Med Limited, and TA Therapeutics, Ltd., while also serving on the Boards of ViaGen, Inc., Clone International, Parnell Pharmaceuticals Holdings Ltd and Pacific Lutheran University. He currently serves on the boards of several private companies in the biopharma and medical device fields. Early in his career, from 1979 to 1995, Mr. Greenwood held various positions at the investment bank J.P. Morgan Chase & Co., where he focused on corporate finance and mergers and acquisitions. Mr. Greenwood received his bachelor's degree from Pacific Lutheran University and his M.B.A. from Harvard Business School.
Albion J. Fitzgerald
Albion J. Fitzgerald has served as a member of our board of directors since May 2014 and as Chairman from July 2014 to April 2021. Mr. Fitzgerald previously served as chief executive officer and chairman of the board of directors of ManageIQ, Inc., a provider of global cloud IT systems management solutions. Mr. Fitzgerald was appointed as a director of ManageIQ in 2007, and served as strategic consultant to the Company from 2007 until April 2012, and as chief executive officer and chairman of the board of directors from April 2012 until ManageIQ, Inc. was acquired by Red Hat, Inc. in December 2012. In 1992 Mr. Fitzgerald co-founded Novadigm, Inc. (NASDAQ: NVDM), an international provider of IT systems management solutions to Fortune 500 companies and government agencies with customers in 26 countries. He served as its chairman and chief technology officer from 1992 and chief executive officer from 1995 until its acquisition by Hewlett Packard in 2004. Prior to Novadigm, Mr. Fitzgerald founded and served as chief executive officer of Telemetrix, Inc., a provider of enterprise IT systems and network management solutions. From 1980 to 1989, Mr. Fitzgerald was a strategic technology consultant to New York University responsible for architecting, building and managing the university’s computer center and campus-wide multi-media network. Mr. Fitzgerald began his technology career at IBM in 1966.
Ms. Nast has served on our board since August 2021. Ms. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry. Most recently, Ms. Nast served as Chief Operating Officer at MindMed, a biotech company developing psychedelic-inspired therapies. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has played a critical role in the development and commercialization of over 100 products. Previously, Ms. Nast was COO at NuGen, a genomics company, and served in executive level positions at Inhale Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals,) BioRad and Pfizer.
Mr. Petkevich has more than 30 years of financial and investment experience in biotechnology and investment banking. Since 2015, Mr. Petkevich has been the Chief Investment Officer of V2M Capital, an investment firm funding life science companies. He currently serves on the board of directors of HingeBio, Inc., a biotechnology company developing bispecific and multispecific antibodies. In 2005, he co-founded BladeRock Capital, LLC, an investment firm specializing in life science companies. Prior to founding BladeRock Capital, Mr. Petkevich founded The Petkevich Group, a biotechnology advisory firm, where he was Chairman and Chief Executive Officer from 1998 to 2005. Between 1989 and 1997, Mr. Petkevich served as Managing Director, as well as Head of Healthcare and Investment Banking at Robertson Stephens & Co. Mr. Petkevich began his career at Hambrecht & Quist, an investment bank, where he served as a Principal, Head of Healthcare Banking and as a biotechnology analyst covering Genentech, Chiron and others. Mr. Petkevich received his bachelor’s degree from Harvard University and his DPhil from the University of Oxford.
Joseph J. Sarret, M.D., J.D.
Chief Executive Officer and Director
Joseph J. Sarret joined CohBar as Chief Executive Officer and Director in May 2021. From 2019 until 2021, Dr. Sarret worked as a consultant in the life science industry, focusing on business development and corporate development activities. From 2015 until 2019, he served as Chief Business Officer at Corium International, Inc. (formerly NASDAQ: CORI), a biopharmaceutical company developing and commercializing transdermal healthcare products. Prior to Corium, Dr. Sarret served in senior leadership roles at Solazyme, Inc. (formerly NASDAQ: SZYM) and Sevident, Inc. From 2005 to 2012, he held several executive management roles, most recently serving as Chief Business Officer at Codexis, Inc. (NASDAQ: CDXS), a publicly traded life sciences company developing novel enzymes for a variety of applications. Earlier in his career, Dr. Sarret worked as a practicing clinician focused on patients with human immunodeficiency virus and an attorney specializing in IP transactional work in the life sciences industry. He received a B.A. in human biology from Stanford University, an M.D. from the University of California, San Francisco School of Medicine and a J.D. from Stanford Law School.
Effie Tozzo, Ph.D.
Dr. Tozzo is currently Chief Scientific Officer at Avilar Therapeutics, a biotechnology company creating a broad and diverse pipeline of extracellular protein degraders as first-in-class medicines for the treatment of serious diseases. As a leader in drug discovery, translational sciences and medicine, Dr. Tozzo has over 26 years of experience in leadership roles in biotech/startups and large pharma organizations. She has initiated and progressed discovery programs to the clinic by building and effectively leading teams in preclinical biology, chemistry, pharmacology, DMPK, safety and biomarker studies in various disease indications.
Over the past 8 years, Dr. Tozzo served at Cellarity (a Flagship Pioneering company) as Senior Vice President, Drug Development and Head of R&D and as Senior Vice President, Translational Sciences at Mitobridge (acquired by Astellas), building teams and strong program pipelines, scientifically leading financing campaigns and pharma partnerships and supporting clinical teams through Phase 1 and clinical proof of concept studies.
Earlier in her career, Dr. Tozzo held leading positions at Merck, Roche, BMS, Millennium, Chiron and ErgoScience. She received her PhD in Molecular and Cellular Endocrinology from the University XI in Paris, France, completed her post-doctoral training in the Endocrine Division at Beth Israel/Harvard Medical School in Boston and has authored over 40 peer-reviewed publications and patents.
Joanne Yun, Ph.D.
Dr. Yun has served on our board since September 2021. Dr. Yun is a partner at Egon Zehnder, one of the world’s preeminent leadership advisory firms and is currently a member of the firm’s Health Practice. In addition to her board and executive leadership work for global pharmaceutical and biotechnology companies, Dr. Yun leads the Research & Development segment of Egon Zehnder’s Health Practice. Prior to joining Egon Zehnder, Dr. Yun was a Director in the Global Oncology Business Unit for Bayer HealthCare Pharmaceuticals with responsibility for oncology program management and new product planning. She has advised on all aspects of research, development, and commercial strategies, including portfolio prioritization, business development, alliance governance, and merger integration. Dr. Yun started her career with Bayer AG as a Bench Chemist and Laboratory Head in the Organic Synthesis Department of Bayer’s Central Research Division in Leverkusen, Germany. She later transitioned into the Corporate Research & Development Planning Department for the Bayer AG Board of Management and then joined theStrategic Planning Department for the Pharmaceuticals Division, where she focused on global merger & acquisition strategies and transactions. Dr. Yun subsequently transferred to Bayer’s North America Business Development & Licensing group. Dr. Yun earned a bachelor’s degree in chemistry and French from Amherst College and a Ph.D. in chemistry from the Massachusetts Institute of Technology. She was a National Institutes of Health (NIH) Postdoctoral Fellow at The Scripps Research Institute and is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Chemical Society.